Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study
A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 108 participants.
Also called NCT05559398
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2/3
- Enrolled
- 108 participants
- Registry
-
NCT05559398 -
2021-000889-16
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- France
- Registry status
- Completed
Technical summary
Registry record NCT05559398. Randomized; quadruple masking; primary purpose treatment. Start 2023-01-03 (actual); primary completion 2025-07-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Glenzocimab for REperfusion in the Setting of Endovascular Therapy for Brain infarctioN: GREEN Study
- Acronym
- GREEN
- Condition
- Stroke, Acute
- Condition
- Stroke, Ischemic
- Intervention (Drug)
- Glenzocimab
- Intervention (Drug)
- Placebo
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
Record details
- Record id
cardio:ct-nct05559398- Content hash
057f5c1dc9afd00db799bdbfc01b9a90e34fd5f510730cf28fcda2bc6764f8fa